ATE213022T1 - Adenovirale vektoren für die gentherapie - Google Patents

Adenovirale vektoren für die gentherapie

Info

Publication number
ATE213022T1
ATE213022T1 AT96915934T AT96915934T ATE213022T1 AT E213022 T1 ATE213022 T1 AT E213022T1 AT 96915934 T AT96915934 T AT 96915934T AT 96915934 T AT96915934 T AT 96915934T AT E213022 T1 ATE213022 T1 AT E213022T1
Authority
AT
Austria
Prior art keywords
helper
gene therapy
adenoviral vectors
preparations
adenoviruses
Prior art date
Application number
AT96915934T
Other languages
English (en)
Inventor
Frank L Graham
Martina Anton
Michael A Rudnicki
Original Assignee
Frank L Graham
Martina Anton
Michael A Rudnicki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frank L Graham, Martina Anton, Michael A Rudnicki filed Critical Frank L Graham
Application granted granted Critical
Publication of ATE213022T1 publication Critical patent/ATE213022T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT96915934T 1995-06-07 1996-06-07 Adenovirale vektoren für die gentherapie ATE213022T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/473,168 US5919676A (en) 1993-06-24 1995-06-07 Adenoviral vector system comprising Cre-loxP recombination
PCT/CA1996/000375 WO1996040955A1 (en) 1995-06-07 1996-06-07 Adenovirus vectors for gene therapy

Publications (1)

Publication Number Publication Date
ATE213022T1 true ATE213022T1 (de) 2002-02-15

Family

ID=23878471

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96915934T ATE213022T1 (de) 1995-06-07 1996-06-07 Adenovirale vektoren für die gentherapie

Country Status (8)

Country Link
US (2) US5919676A (de)
EP (1) EP0832267B1 (de)
JP (1) JP3492700B2 (de)
AT (1) ATE213022T1 (de)
AU (1) AU724161B2 (de)
CA (1) CA2220997C (de)
DE (1) DE69619110T2 (de)
WO (1) WO1996040955A1 (de)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164782A1 (en) 1999-02-10 2002-11-07 Gregory Richard J. Adenovirus vectors for gene therapy
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US6730507B1 (en) 1993-06-24 2004-05-04 Merck & Co., Inc. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration
US20020146392A1 (en) * 1993-06-24 2002-10-10 Frank L. Graham Helper dependent adenovirus vectors based on site-specific recombinases
US20020136708A1 (en) * 1993-06-24 2002-09-26 Graham Frank L. System for production of helper dependent adenovirus vectors based on use of endonucleases
US6080569A (en) * 1993-06-24 2000-06-27 Merck & Co., Inc. Adenovirus vectors generated from helper viruses and helper-dependent vectors
US7045347B2 (en) 1993-06-24 2006-05-16 Advec, Inc. Helper dependent adenovirus vectors based on integrase family site-specific recombinases
US6379943B1 (en) * 1999-03-05 2002-04-30 Merck & Co., Inc. High-efficiency Cre/loxp based system for construction of adenovirus vectors
JP4216350B2 (ja) * 1994-09-19 2009-01-28 大日本住友製薬株式会社 動物細胞感染用の組換えｄｎａウイルスベクター
US6964861B1 (en) * 1998-11-13 2005-11-15 Invitrogen Corporation Enhanced in vitro recombinational cloning of using ribosomal proteins
US20060110798A1 (en) * 1995-06-07 2006-05-25 Graham Frank L Cells expressing recombinase useful for adenovirus vector production and control of gene expression
EP0937098B1 (de) 1995-06-07 2002-08-14 Invitrogen Corporation Rekombinatorische klonierung in vitro unter verwendung genmanipulierter rekombinationsorte
US6143557A (en) * 1995-06-07 2000-11-07 Life Technologies, Inc. Recombination cloning using engineered recombination sites
US6720140B1 (en) 1995-06-07 2004-04-13 Invitrogen Corporation Recombinational cloning using engineered recombination sites
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6265212B1 (en) 1995-06-15 2001-07-24 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
DE69633565T3 (de) 1995-06-15 2013-01-17 Crucell Holland B.V. Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie
FR2737501B1 (fr) * 1995-07-31 1997-10-24 Transgene Sa Nouveaux virus auxiliaires pour la preparation de vecteurs viraux recombinants
DE19623203A1 (de) * 1995-11-24 1997-05-28 Max Planck Gesellschaft Virusvektor für den Transfer stabiler Episome
US20020193580A1 (en) * 1995-12-15 2002-12-19 Mitchell Lloyd G. Methods and compositions for use in spliceosome mediated RNA trans-splicing
US20030027250A1 (en) * 1995-12-15 2003-02-06 Mitchell Lloyd G. Methods and compositions for use in spliceosome mediated RNA trans-splicing
US20060088938A1 (en) * 1995-12-15 2006-04-27 Mitchell Lloyd G Methods and compositions for use in spliceosome mediated RNA trans-splicing in plants
WO1997025446A1 (en) * 1996-01-05 1997-07-17 Genetic Therapy, Inc. Recombinase-mediated generation of adenoviral vectors
US6228646B1 (en) * 1996-03-07 2001-05-08 The Regents Of The University Of California Helper-free, totally defective adenovirus for gene therapy
US6630346B1 (en) * 1996-06-20 2003-10-07 Merck & Co., Inc. Gene therapy for obesity
US7232899B2 (en) 1996-09-25 2007-06-19 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
US6475789B1 (en) * 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
EA199900355A1 (ru) 1996-10-01 2000-08-28 Джерон Корпорейшн Теломераза обратная тринскриптаза
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
US5994132A (en) * 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors
DE69738737D1 (de) 1996-12-16 2008-07-10 Eisai R&D Man Co Ltd Verfahren zur herstellung von retroviralen vektoren für die gentherapie
US6403370B1 (en) 1997-02-10 2002-06-11 Genstar Therapeutics Corporation Oncolytic/immunogenic complementary-adenoviral vector system
US5851808A (en) * 1997-02-28 1998-12-22 Baylor College Of Medicine Rapid subcloning using site-specific recombination
CA2283253A1 (en) * 1997-03-04 1998-09-11 Baxter International Inc. Adenovirus e1-complementing cell lines
US20050013825A1 (en) * 1997-04-18 2005-01-20 Geron Corporation Vaccine containing the catalytic subunit of telomerase for treating cancer
US7622549B2 (en) * 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
US7413864B2 (en) * 1997-04-18 2008-08-19 Geron Corporation Treating cancer using a telomerase vaccine
WO1999014354A1 (en) * 1997-09-19 1999-03-25 The Trustees Of The University Of The Pennsylvania Methods and vector constructs useful for production of recombinant aav
US7351578B2 (en) * 1999-12-10 2008-04-01 Invitrogen Corp. Use of multiple recombination sites with unique specificity in recombinational cloning
DE69836092T2 (de) 1997-10-24 2007-05-10 Invitrogen Corp., Carlsbad Rekombinatorisches klonieren unter verwendung von nukleinsaüren mit rekombinationsstellen
AU1539499A (en) * 1997-11-25 1999-06-15 Princeton University Method for preparing adenovirus vectors, vectors so prepared, and uses thereof
DE19807265C2 (de) * 1998-02-20 2000-01-05 Centeon Pharma Gmbh Adenoviraler Transfervektor für den Gentransport einer DNA-Sequenz
US6337200B1 (en) * 1998-03-31 2002-01-08 Geron Corporation Human telomerase catalytic subunit variants
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
IL141403A0 (en) * 1998-08-28 2002-03-10 Univ Duke Deleted adenoviruses and methods of making and administering the same
US6303362B1 (en) * 1998-11-19 2001-10-16 The Board Of Trustees Of The Leland Stanford Junior University Adenoviral vector and methods for making and using the same
CA2360796A1 (en) * 1999-02-04 2000-08-10 Merck & Co., Inc. Improved helper dependent vector system for gene therapy
EP1157103A2 (de) * 1999-02-18 2001-11-28 Merck & Co., Inc. Herstellung von helferabhängigen adenovirusvektoren unter verwendung von endonucleasen
DE60042969D1 (de) * 1999-03-02 2009-10-29 Life Technologies Corp Zubereitungen und methoden zur verwendung in rekombinatorischem klonen von nukleinsäuren
EP1159439B1 (de) 1999-03-05 2014-01-08 Advec Inc. Verbessertes system für die konstruktion von adenoviralen vektoren
US20030215423A1 (en) * 1999-04-01 2003-11-20 Merck & Co., Inc. Gene therapy for obesity
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
EP1165817A1 (de) * 1999-04-06 2002-01-02 Merck & Co., Inc. Verwendung von helferabhängigen adenoviralen vektoren alternativer serotypen zur wiederholten vektorverabreichung
DK1820853T3 (da) * 1999-04-06 2011-12-19 Wisconsin Alumni Res Found Rekombinant influenzavirus til vacciner og genterapi
CA2388301C (en) 1999-10-22 2011-01-04 Aventis Pasteur Limited Modified gp100 and uses thereof
ATE391789T1 (de) 1999-12-10 2008-04-15 Invitrogen Corp Verwendung einer vielzahl von rekombinationsstellen mit einzigartiger spezifität beim rekombinatorischen klonen
US6867022B1 (en) * 2000-01-21 2005-03-15 Regents Of The University Of Michigan Replication deficient adenovirus vectors and methods of making and using them
US7132277B1 (en) * 2000-01-31 2006-11-07 Merck & Co., Inc. Helper dependent vector system for gene therapy
AU5533601A (en) 2000-04-14 2001-10-30 Wisconsin Alumni Res Found Viruses comprising mutation ion channel protein
US7851212B2 (en) 2000-05-10 2010-12-14 Sanofi Pasteur Limited Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
US7244560B2 (en) * 2000-05-21 2007-07-17 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
AU2001280576A1 (en) * 2000-07-18 2002-01-30 Uab Research Foundation Tissue-specific self-inactivating gene therapy vector
US7198924B2 (en) * 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
EP1317560A4 (de) * 2000-09-08 2005-10-05 Gen Hospital Corp Sich selbst neuordnende dna vektoren(18.03.02)
WO2002027007A2 (en) 2000-09-25 2002-04-04 Regents Of The University Of Michigan Production of viral vectors
JPWO2002041922A1 (ja) * 2000-11-24 2004-03-25 丸山　弘樹 生体に導入された遺伝子の発現産物の活性を制御する方法
US20040126774A1 (en) * 2001-01-08 2004-07-01 Mitchell Lioyd G. Correction of factor VIII genetic defects using spliceosome mediated RNA trans splicing
EP1379281A4 (de) * 2001-03-26 2005-05-18 Univ Leland Stanford Junior Helfer-abhängiges adenovirus-vektorsystem und verfahren für seine verwendung
US20030077804A1 (en) * 2001-04-19 2003-04-24 Invitrogen Corporation Compositions and methods for recombinational cloning of nucleic acid molecules
CA2448505A1 (en) * 2001-05-21 2002-11-28 Invitrogen Corporation Compositions and methods for use in isolation of nucleic acid molecules
CA2451957A1 (en) * 2001-06-28 2003-01-09 Phenogene Therapeutiques Inc. Methods, vectors, cell lines and kits for selecting nucleic acids having a desired feature
US6838285B2 (en) 2001-09-18 2005-01-04 Becton Dickinson Site specific recombinase based method for producing adenoviral vectors
EP1516055A4 (de) * 2002-01-24 2007-08-08 Scripps Research Inst Faserschaftmodifikationen für effizientes zielen
US7399753B2 (en) * 2002-02-25 2008-07-15 Virxsys Corporation Trans-splicing mediated photodynamic therapy
ATE369895T1 (de) 2002-04-09 2007-09-15 Sanofi Pasteur Ltd Modifizierte cea nucleinsäure und expressionsvektoren
WO2005035773A2 (en) * 2003-10-08 2005-04-21 Sanofi Pasteur, Inc. Modified cea /b7 vector
WO2004050680A2 (en) * 2002-05-08 2004-06-17 Intronn, Inc. Use of spliceosome mediated rna trans-splicing to confer cell selective replication to adenoviruses
US8304233B2 (en) 2002-06-04 2012-11-06 Poetic Genetics, Llc Methods of unidirectional, site-specific integration into a genome, compositions and kits for practicing the same
AU2003269220A1 (en) * 2002-09-27 2004-04-19 Powderject Research Limited Nucleic acid constructs for gene expression
AU2003285009B2 (en) * 2002-10-23 2010-10-07 Virxsys Corporation Screening methods for identification of efficient pre-trans-splicing molecules
US20040203133A1 (en) * 2003-01-07 2004-10-14 Anja Ehrhardt Helper dependent adenoviral vector system and methods for using the same
JP2007525175A (ja) 2003-04-23 2007-09-06 ウィスコンシン アルムニ リサーチ ファウンデイション 突然変異した膜タンパク質をその機能性の一部ウイルス
WO2005028615A2 (en) * 2003-06-26 2005-03-31 Invitrogen Corporation Methods and compositions for detecting promoter activity and expressing fusion proteins
DE602004027538D1 (de) 2003-12-01 2010-07-15 Life Technologies Corp Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon
US7968334B2 (en) * 2004-01-23 2011-06-28 Virxsys Corporation Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing
WO2005070948A1 (en) * 2004-01-23 2005-08-04 Intronn, Inc. Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated rna trans splicing
WO2005070023A2 (en) * 2004-01-23 2005-08-04 Intronn, Inc. Expression of apoa-1 and variants thereof using spliceosome mediated rna trans-splicing
US20060094110A1 (en) * 2004-07-30 2006-05-04 Mcgarrity Gerard J Use of spliceosome mediated RNA trans-splicing for immunotherapy
US20060134658A1 (en) * 2004-08-09 2006-06-22 Garcia-Blanco Mariano A Use of RNA trans-splicing for generation of interfering RNA molecules
CN101094688B (zh) 2004-09-13 2013-05-01 建新公司 多聚构建体
DE102004047492B4 (de) * 2004-09-23 2006-07-20 Jost-Werke Gmbh & Co. Kg Verfahren zum Übertragen von elektrischer, pneumatischer oder hydraulischer Energie sowie ein Energieübertragungssystem
US7871795B2 (en) 2004-10-08 2011-01-18 Virxsys Corporation Targeted trans-splicing of highly abundant transcripts for in vivo production of recombinant proteins
JP5053850B2 (ja) * 2004-10-08 2012-10-24 バークシス コーポレーション 抗体遺伝子導入および抗体ポリペプチド産生のためのｒｎａトランススプライシングの使用
CN101103103A (zh) 2004-11-19 2008-01-09 威斯康星旧生研究基金会 具有串联转录单位的重组流感病毒载体
US7696335B2 (en) * 2005-10-13 2010-04-13 Bc Cancer Agency Kits for multiple non-cross reacting recombination reactions utilizing loxP sequences
AR059089A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
CN101404927A (zh) 2006-02-09 2009-04-08 建新公司 慢速脑室内递送
JP2009532352A (ja) 2006-03-31 2009-09-10 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ワクチンのための高力価組み換えインフルエンザ・ウィルス
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
ES2337973B8 (es) * 2008-05-16 2011-07-21 Proyecto De Biomedicina Cima, S.L. Adenovirus auxiliares auto-inactivantes para la produccion de adenovirus recombinantes de alta capacidad.
JP2013507990A (ja) 2009-10-26 2013-03-07 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ベロ細胞において増強された複製を有する高力価の組換えインフルエンザウイルス
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
ES2655051T3 (es) 2011-08-26 2018-02-16 Wisconsin Alumni Research Foundation Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas
SG10201604810UA (en) 2012-02-07 2016-08-30 Global Bio Therapeutics Inc Compartmentalized method of nucleic acid delivery and compositions and uses thereof
WO2014115022A1 (en) 2013-01-25 2014-07-31 Baylor College Of Medicine A helper-dependent adenoviral gene therapy delivery and expression system
JP2016524915A (ja) 2013-07-15 2016-08-22 ウィスコンシン アルムニ リサーチ ファンデイション Ｍｄｃｋ、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス
CN105813579B (zh) 2013-08-08 2019-05-07 全球生物疗法有限公司 用于微创手术过程的夹具装置和其应用
EP3564379A1 (de) 2013-09-13 2019-11-06 California Institute of Technology Selektive rückgewinnung
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
AU2016366549B2 (en) 2015-12-11 2022-11-10 California Institute Of Technology Targeting peptides for directing adeno-associated viruses (AAVs)
JP2019510481A (ja) 2016-02-19 2019-04-18 ウィスコンシン アルムニ リサーチ ファンデイション ワクチン開発のための改善されたｂ型インフルエンザウイルス複製
KR20240093758A (ko) 2017-04-21 2024-06-24 베이롤 칼리지 오브 메드신 종양용해성 바이러스요법 및 면역요법
WO2019084310A1 (en) 2017-10-25 2019-05-02 Yoshihiro Kawaoka HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
US11389523B2 (en) 2018-08-20 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein
US11149256B2 (en) 2018-09-26 2021-10-19 California Institute Of Technology Adeno-associated virus compositions for targeted gene therapy
EP3914295A2 (de) 2019-01-23 2021-12-01 Yoshihiro Kawaoka Mutationen zur verleihung von genetischer stabilität gegenüber zusätzlichen genen bei grippeviren
WO2020163804A1 (en) 2019-02-08 2020-08-13 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
CN114929269A (zh) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) 用于疫苗开发的改进的流感病毒复制
WO2021041624A2 (en) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs
JP7385742B2 (ja) * 2019-10-23 2023-11-22 ジェネンメド カンパニー リミテッド ヘルパープラスミドベースのガットレスアデノウイルス生産システム
JP2023511444A (ja) 2020-01-24 2023-03-17 ウィスコンシン アルムニ リサーチ ファンデイション 安定化されたｎａを有する組換えインフルエンザウイルス
IL296417A (en) 2020-03-15 2022-11-01 Proteinea Inc Production of recombinant proteins in insects
WO2021195410A1 (en) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
CN118139655A (zh) 2021-08-13 2024-06-04 特里奥万斯控股公司 皮肤替代组合物及其产生和使用方法
CN114410683B (zh) * 2022-01-12 2023-11-28 中国人民解放军空军军医大学 一种基于Cre-lox重组系统的RIM3-RNAi及其应用
CN114369623B (zh) * 2022-01-12 2023-07-07 中国人民解放军空军军医大学 一种基于Cre-lox重组系统的Synaptotagmin2-RNAi及其应用
WO2026107113A1 (en) 2024-11-12 2026-05-21 Calidi Biotherapeutics (Nevada), Inc. MODIFIED CELLS FOR PROGRAMMING EXTRA ENVELOPED VIRUSES (EEVs) AND THEIR USE FOR PRODUCING THE EEVs, THE PROGRAMMED EEVs AND USES THEREOF

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4510245A (en) * 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
ZA858044B (en) * 1984-11-01 1987-05-27 American Home Prod Oral vaccines
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4920211A (en) * 1988-01-04 1990-04-24 Vanderbilt University Mutated adenovirus E1A gene for E1A promoter stimulation
FR2681786A1 (fr) * 1991-09-27 1993-04-02 Centre Nat Rech Scient Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
WO1993019092A1 (fr) * 1992-03-19 1993-09-30 Centre National De La Recherche Scientifique Adenovirus recombinants defectifs exprimant des proteines caracteristiques du virus epstein-barr
DE69334238D1 (de) * 1992-09-25 2008-09-25 Aventis Pharma Sa Adenovirus vektoren für die übertragung fremder gene in zellen des zentralen nervensystems, insbesondere im gehirn
EP0705344B8 (de) * 1993-06-24 2006-05-10 Advec Inc. Adenovirus vektoren für gentherapie
US7252989B1 (en) * 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
JP4216350B2 (ja) * 1994-09-19 2009-01-28 大日本住友製薬株式会社 動物細胞感染用の組換えｄｎａウイルスベクター

Also Published As

Publication number Publication date
DE69619110T2 (de) 2002-07-18
CA2220997A1 (en) 1996-12-19
DE69619110D1 (de) 2002-03-21
WO1996040955A1 (en) 1996-12-19
US20010041173A1 (en) 2001-11-15
US5919676A (en) 1999-07-06
AU724161B2 (en) 2000-09-14
JP3492700B2 (ja) 2004-02-03
CA2220997C (en) 2007-04-24
EP0832267B1 (de) 2002-02-06
EP0832267A1 (de) 1998-04-01
AU5889796A (en) 1996-12-30
JPH11506334A (ja) 1999-06-08

Similar Documents

Publication Publication Date Title
DE69619110D1 (de) Adenovirale vektoren für die gentherapie
ATE336587T1 (de) Adenoviren-vektor systeme und zelllinien
BG102612A (en) Complementary adenoviral vector systems and cellular lines
NO982417D0 (no) Vektorer og fremgangsmÕter for genoverf°ring til celler
CA2213343A1 (en) Chimeric adenoviral fiber protein and methods of using same
PT797676E (pt) Vector adenoviral recombinante e metodos de utilizacao
WO1996007734A3 (en) Recombinant adenovirus comprising a chimeric penton base protein
FI951138A7 (fi) Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
CY1105440T1 (el) Κυτταρικες σειρες και κατασκευες χρησιμες στην παραγωγη ε1-διαγραμμενων αδενοϊων εν τη απουσια αδενοϊων ικανων αναπαραγωγης
ATE387492T1 (de) Verfahren und zusammensetzung zur konservierung von adenoviren
DE69731611D1 (de) Eine Zusammensetzung enthaltend eine Detergenz und einen ein Tumorsuppressorgen kodierenden, adenoviralen Vektor
MX9705937A (es) Procedimiento de preparacion de genoma de adenovirus recombinantes.
CY1111931T1 (el) Φορεις αδενοϊων για την αγωγη νοσου
FI961666A7 (fi) Restenosiksen geeniterapia, jossa käytetään adenovirusvektoria
WO2000049168A3 (en) Helper adenovirus / helper-dependent adenovirus vector system based on site-specific recombinase activity
ATE342998T1 (de) Replikation -defektive baculoviren expressionssystem
HUP9802587A2 (hu) Glükózzal indukálható rekombináns virális vektor, ezt tartalmazó gyógyszerkészítmény és ezzel transzformált sejtek
WO2000012741A3 (fr) Systeme d'expression inductible
AU3880900A (en) Surface localized colligin/hsp47 in carcinoma cells
AU1099697A (en) Novel xylanases, genes encoding them, and uses thereof
EP0843006A3 (de) Rekombinante prostataspezifische Antigen-Vektoren und diese verwendende Assays
EP1185306A4 (de) Verwendung von viralen vektoren und geladenen molekülen für die gentherapie

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties